glp-1 price drop A Cost That's Hard to (G)u(LP-1) Down 🎤 PRICE DROP 🎤 Great

Rising global prevalence of obesity and type 2 diabetes is a primary growth driver for the market

Continuing on to discontinuation rates we see another very interesting nugget that I have bolded below: Discontinuation rates due to adverse events were 12.2% and 18.2% with retatrutide 9 mg and 12 mg, respectively, compared to 4.0% with placebo

As a retrospective cohort analysis, it is inherently subject to biases such as selection bias

Abnormal cholesterol levels qualify

: 2016 UpToDate Summary adjunct therapy to reduce Hb A1c levels in patients with Type 2 diabetes who are inadequately controlled by other hypoglycemic agents

GLP-1 medications are not appropriate for everyone